Every letter we have printed

Hand hygiene before anything else is the single highest-yield step in every published account of technique in any setting, and it is the step most often skipped because it is the least visible.

Sharps disposal is not an afterthought and the article treats it as one. A rigid container, obtained before it is needed rather than after, is the whole of the advice, and it belongs at the start of the sequence rather than at the end.

The unit confusion in this area is a design problem rather than an education problem. A syringe graduated for one purpose, used to measure a volume of something else, will produce errors at a rate determined by the markings and not by the diligence of the person reading them.

You recommend writing the concentration on the vial. I would add: write it on the box as well. My vial label came off in the fridge and I lost the only record of what diluent volume I had used.

A methodological plea. Publish the purchase date, the arrival date and the determination date for every blind result. Without all three, a poor figure cannot be attributed between manufacture, freight and storage, and every party will attribute it wherever suits them.

The distinction that matters is not blind against named but who chose the sample. A blind submission of a vial the seller selected is not blind in any sense that protects the reader, and the word is doing all the work in that sentence.

The trials are conducted with pharmaceutical-grade material under supervision. Whatever they establish, they establish about that material in that setting, and the extension of their findings to a research-supply context is an assumption rather than a result.

I have read four of these studies and none reported what participants were told about the possibility of regain. Expectation is a variable in any outcome that includes behaviour, and it is entirely unmeasured across the set.

Your piece treats maintenance as a single question. In the accounts I read there are at least three: maintaining a weight, maintaining a metabolic marker and maintaining a behaviour. They come apart in practice and are almost always discussed together.

Intermittent use is studied almost nowhere and practised widely, which is an uncomfortable combination for anybody trying to write about it responsibly. The honest position is that the evidence base is close to empty, and saying so is more useful than assembling anecdotes.

Nothing in the published evidence supports or refutes indefinite continuation, because nobody has run a study of that length. Where the honest answer is that the question is open, saying so is not a failure of reporting.

Your worked example uses valley-to-valley integration throughout. Tangential skim on a shoulder eluting off the main peak will hand a slice of the impurity back to the product and move the figure in the flattering direction. It is a legitimate choice with a published rationale, and it is invisible on the certificate.

I would like to see the phrase "area normalisation" appear on certificates that use it. It is not a defect; it is a method with a stated assumption, which is that everything present absorbs equally at the detection wavelength. The assumption is false for peptides and the arithmetic proceeds regardless.

We changed to core-shell particles two years ago for exactly the reasons you set out, and I would add one that you do not mention. The pressure headroom means a column survives a badly filtered sample instead of blocking, which in a service laboratory is worth more than the extra plate count.

On the section about diode-array detection and peak purity, I would add that true peak purity assessment requires library matching or at least spectral comparison across the peak width. A homogeneous spectrum tells you the peak is probably pure. A spectrum that shifts across the peak tells you it is not, and that information closes a gap the article identifies correctly.

I have written to correct this department twice and both letters were printed with a reply that conceded the point. That is rarer than it should be and it is why I keep reading.

Maintenance is discussed almost entirely in terms of what is taken and almost never in terms of what is measured. A phase defined by stability needs a monitoring plan more than an acute phase does, and I see far less written about the second.

The word maintenance carries an assumption that the maintained state is stable. Everything in the published record suggests it is a position held against a gradient, and the vocabulary of maintenance makes the effort involved invisible to people planning around it.

Social reasons are entirely absent from every list I have seen. A change in household circumstances, a partner’s view, a change of job — these end arrangements regularly and appear in no taxonomy anywhere.

The word discontinuation implies an endpoint that has been reached. A great many of the accounts I read describe an intention to resume that was never acted on, which is a different phenomenon recorded under the same heading.

You describe blind purchasing as the gold standard. It is the minimum standard. The gold standard is blind purchasing, repeated, with retained samples, published in full including the dull results, and nothing in this market comes close to that.

Community-funded testing has solved the money problem in a handful of cases, and it introduces a new one: the group choosing the target has its own preferences about the answer. It is a better arrangement than seller-funded testing and it is not neutral.

We ask customers to send the vial unopened and we record the seal condition on arrival. It has produced two useful findings in three years, both about transit rather than about the supplier, and neither would have been visible if the sample had arrived as a powder in a bag.

On the archive point: a public record of submissions by vendor would be gamed within a month. Vendors would submit under the names of resellers, or through intermediaries, and the archive would show a distribution as selected as the current one but with a veneer of completeness.

Speaking as a former quality manager, the safeguard that matters is whether the analyst knows whose sample it is before the run. Blinding at the bench costs nothing and removes the whole class of problem your article describes. It is a question worth putting to each of the four.

The published curves are almost always means with standard errors, which narrow as the sample grows and give an impression of precision about a population that says nothing about an individual. Standard deviations would be more honest and are rarely plotted.

The word plateau implies a stable state and what the data usually shows is a decelerating one. Those are different shapes with different implications for what happens next, and the distinction is lost in every summary I read.

The trial schedules escalated on a fixed calendar regardless of response, which is a design choice for comparability rather than a recommendation. Reading them as optimal is reading a protocol as advice.

I had a nine-week gap last year because my supplier stopped answering messages. Nobody in any clinical setting I dealt with treated that as a pharmacological event. Your framing of supply interruption as a dosing decision is the first time I have seen it written down.

A plateau is a physiological outcome rather than a failure of dosing, and the reflex to escalate at that point is worth examining. Your piece hints at this and could say it outright: the curve flattening is what the curve does.

The training studies in this area are mostly short, mostly small and mostly in populations selected for being able to train. That is not a criticism of the studies; it is a description of what can be concluded from them.

An activity component in a trial is also an attention component, and the two cannot be separated in an unblinded design. Some part of any benefit attributed to training is attributable to contact with the study team.

One more argument against reasoning past the ceiling: the exposure achieved depends on the material as well as the dose, and where peptide content is undocumented the dose is nominal. Arithmetic performed on an uncertain quantity is not made more precise by making the quantity larger.

In this market the nominal dose is derived from an assumed concentration, so the real ceiling question is a question about content. A figure calculated from a label is not a dose in the sense the trial literature uses the word.

I want to object to the framing of dose reduction as measurement. In practice it is experienced as failure, and telling people it is a thermostat does not change how the appointment feels. The language problem is real and you have solved it rhetorically rather than actually.

The target dose and the maximum dose are different concepts and the trade uses them as synonyms. A target is where the trial aimed; a maximum is where the label stops. Somebody doing well below the target has not failed to reach anything.

The follow-up periods in these studies are shorter than the period readers care about. Reporting that plainly, rather than extending the observed trajectory in the reader’s imagination, is the honest treatment and your piece does it.

Composition endpoints are collected in a minority of these studies and reported in fewer. A weight curve after withdrawal without a composition measurement leaves the most interesting question unanswered.

You describe the maintenance strategy of stepping down one dose and holding for eight to twelve weeks as something clinicians report doing, and then say it is not a recommendation. That distinction will be lost on most readers, and printing the protocol makes you a source for it whether you intend to be or not.

Intermittent schedules are being used and are essentially unstudied, and the pharmacokinetics make the reasoning awkward: with a long half-life the concentration does not fall to nothing between doses, so an interrupted schedule is not the same as stopping and restarting.